Patents Assigned to Vernalis (R&D) Ltd
-
Patent number: 10278972Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.Type: GrantFiled: April 20, 2017Date of Patent: May 7, 2019Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTDInventors: András Kotschy, Zoltán Szlávik, Márton Csékei, Attila Paczal, Zoltán Szabó, Szabolcs Sipos, Gábor Radics, Ágnes Proszenyák, Balázs Bálint, Alain Bruno, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Françoise Perron-Sierra
-
Patent number: 10258626Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.Type: GrantFiled: February 9, 2017Date of Patent: April 16, 2019Assignees: LES LABORATORIES SERVIER, VERNALIS (R&D) LTDInventors: Thierry Le Diguarher, Patrick Casara, Jérôme-Benoît Starck, Jean-Michel Henlin, James Edward Paul Davidson, James Brooke Murray, Christopher John Graham, I-Jen Chen, Olivier Geneste, John Hickman, Stéphane Depil, Arnaud Le Tiran, Mikl{dot over (o)}s Nyerges, Guillaume De Nanteuil
-
Patent number: 10227358Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R13, Ra, Rb, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.Type: GrantFiled: June 22, 2016Date of Patent: March 12, 2019Assignees: LES LABORATOIRES SERVIER, VERNALIS &R&D) LTD.Inventors: Zoltan Szlavik, András Kotschy, Maïa Chanrion, Didier Demarles, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, Szabolcs Sipos, Attila Paczal, Balazs Balint
-
Patent number: 9944620Abstract: Compounds of formula (I) wherein Ra, Rb, Rc, Rd, T, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.Type: GrantFiled: July 22, 2014Date of Patent: April 17, 2018Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTDInventors: Arnaud Le Tiran, Thierry Le Diguarher, Jéròme-Benoît Starck, Jean-Michel Henlin, Guillaume De Nanteuil, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen
-
Patent number: 9920066Abstract: Compounds of formula (I) are A2B receptor antagonists: Wherein R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R4 is C1-C3 alkyl, C2-C3 alkenyl, —N(—R5)—R6, or optionally substituted heteroarylmethylamino; and R5 and R6 are independently selected from hydrogen or C1-C3 alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated rinType: GrantFiled: February 20, 2017Date of Patent: March 20, 2018Assignee: Vernalis (R&D) Ltd.Inventors: Allan Jordan, Simon Bedford, Klenke Burkhard, Ian Yule, Karine Poullennec
-
Patent number: 9809574Abstract: Compounds of formula (I): wherein Het, R3, R4, R5, R7, R8, R9, T, p, p?, q, and q? are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.Type: GrantFiled: July 22, 2014Date of Patent: November 7, 2017Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTDInventors: James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Claire Walmsley, Mark Dodsworth, Johannes W. G. Meissner, Paul Brough, Imre Fejes, János Tatai, Miklós Nyerges, András Kotschy, Zoltán Szlávik, Olivier Geneste, Arnaud Le Tiran, Thierry Le Diguarher, Jean-Michel Henlin, Jérôme-Benoît Starck, Anne-Françoise Guillouzic, Guillaume De Nanteuil
-
Patent number: 9765056Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R3, R4, R5, A1, A2, T and W are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.Type: GrantFiled: July 22, 2014Date of Patent: September 19, 2017Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTDInventors: Patrick Casara, Thierry Le Diguarher, Jean-Michel Henlin, Jéröme-Benoit Starck, Arnaud Le Tiran, Guillaume De Nanteuil, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Claire Walmsley, Christopher John Graham, Stuart Ray, Daniel Maddox, Simon Bedford
-
Patent number: 9718793Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C?O)—, —(C?S)—, —SO.sub.Type: GrantFiled: June 27, 2013Date of Patent: August 1, 2017Assignees: Vernalis (R&D) Ltd., Cancer Research Technology Limited, The Institute of Cancer ResearchInventors: Martin James Drysdale, Brian William Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen Elizabeth James, Kwai Ming Cheung, Thomas Peter Matthews
-
Patent number: 9670227Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.Type: GrantFiled: December 19, 2014Date of Patent: June 6, 2017Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTDInventors: András Kotschy, Zoltán Szlávik, Márton Csékei, Attila Paczal, Zoltán Szabó, Szabolcs Sipos, Gábor Radics, Ágnes Proszenyák, Balázs Bálint, Alain Bruno, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Françoise Perron-Sierra
-
Patent number: 9610290Abstract: Compounds of formula (I) are A2B receptor antagonists: Wherein R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R4 is C1-C3 alkyl, C2-C3 alkenyl, —(—R5)—R6, or optionally substituted heteroarylmethylamino; and R5 and R6 are independently selected from hydrogen or C1-C3 alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated ringType: GrantFiled: July 20, 2015Date of Patent: April 4, 2017Assignee: Vernalis (R&D) Ltd.Inventors: Allan Jordan, Simon Bedford, Klenke Burkhard, Ian Yule, Karine Poullennec
-
Patent number: 9603854Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.Type: GrantFiled: July 15, 2015Date of Patent: March 28, 2017Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTDInventors: Thierry Le Diguarher, Patrick Casara, Jérôme-Benoît Starck, Jean-Michel Henlin, James Edward Paul Davidson, James Brooke Murray, Christopher John Graham, I-Jen Chen, Olivier Geneste, John Hickman, Stéphane Depil, Arnaud Le Tiran, Miklos Nyerges, Guillaume De Nanteuil
-
Patent number: 9604975Abstract: Compounds of formula (I) have checkpoint kinase 1 (CHK1) inhibitory activity: wherein R1, R2, R5 and R6 are independently selected from hydrogen, hydroxy, methyl, trifluoromethyl, hydroxymethyl, methoxy, trifluoromethoxy, methylamino and dimethylamino; R3, and R4 are independently selected from hydrogen, hydroxy, C1-C3 alkyl, fluoro-(C1-C3)-alkyl, hydroxy-(C1-C3)-alkyl, C1-C3 alkoxy, fluoro-(C1-C3)-alkoxy, hydroxy-(C1-C3)-alkoxy, —N(R11)—R12, -Alk-N(R11)—R12, —O-Alk-N(R11)—R12, —C(?O)OH, carboxy-(C1-C3)-alkyl, or —C(?O)—NH—R13; Alk is a straight or branched chain divalent C1-C6 alkylene radical; R7 and R8 are independently selected from hydrogen, hydroxy, or C1-C3 alkoxy; X is a straight chain divalent C1-C3 alkylene radical, optionally substituted on one or more carbons by R9 and/or R10; W is selected from —C(?O)—N(—R16)— or —N(—R17)—C(?O)—; Y is hydrogen, C1-C3 alkyl, C1-C3 alkoxy, or halo; and Q is selected from optionally substituted phenyl, optionally substituted cyclohexyl, or an optionally substituType: GrantFiled: November 10, 2014Date of Patent: March 28, 2017Assignee: Vernalis (R&D) LtdInventors: Stephen Stokes, Nicolas Foloppe, Andrea Fiumana, Martin Drysdale, Simon Bedford, Paul Webb
-
Patent number: 9598427Abstract: Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.Type: GrantFiled: July 13, 2015Date of Patent: March 21, 2017Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTDInventors: Arnaud Le Tiran, Thierry Le Diguarher, Jérôme-Benoît Starck, Jean-Michel Henlin, Anne-Françoise Guillouzic, Guillaume De Nanteuil, Olivier Geneste, Imre Fejes, Janos Tatai, Miklos Nyerges, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Didier Durand
-
Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
Patent number: 9597341Abstract: Compounds of formula (I): wherein X, Y, A1, A2, Ra, Rb, Rc, Rd, R3, R4, T and R5 are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.Type: GrantFiled: July 16, 2015Date of Patent: March 21, 2017Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTDInventors: Arnaud Le Tiran, Thierry Le Diguarher, Jérõme-Benoĩt Starck, Jean-Michel Henlin, Anne-Françoise Guillouzic, Guillaume De Nanteuil, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen -
Publication number: 20170020850Abstract: The present invention is directed to arylpyrrolopyridine derivatives of Formula A: The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.Type: ApplicationFiled: October 7, 2016Publication date: January 26, 2017Applicants: H. Lundebck A/S, Vernalis (R&D) Ltd.Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
-
Patent number: 9499542Abstract: The present invention is directed to arylpyrrolopyridine derivatives of formula (A) (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease cancer.Type: GrantFiled: April 14, 2014Date of Patent: November 22, 2016Assignees: H. Lundbeck A/S, Vernalis (R&D) Ltd.Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
-
Patent number: 9475800Abstract: Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: Wherein Ar1 is optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Ar2 is optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Ar3 is a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.Type: GrantFiled: March 9, 2015Date of Patent: October 25, 2016Assignee: VERNALIS (R&D) LTD.Inventors: Stephen Roughley, Steven Walls, Terance Hart, Rachel Parsons, Paul Brough, Christopher Graham, Alba Macias
-
Patent number: 9393248Abstract: The present invention is directed to aminopyridine derived compounds of formula (A) The compounds are considered useful for the treatment of diseases associated with LRRK2 such as a Lewy body dementia, Parkinson's disease or cancer.Type: GrantFiled: March 16, 2016Date of Patent: July 19, 2016Assignees: H. Lundbeck A/S, Vernalis (R&D) Ltd.Inventors: Gitte Kobberøe Mikkelsen, Laurent David, Stephen Watson, Garrick Paul Smith, Douglas Stewart Williamson, I-Jen Chen
-
Publication number: 20160184317Abstract: The present invention is directed to aminopyridine derived compounds of formula (A) The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.Type: ApplicationFiled: March 16, 2016Publication date: June 30, 2016Applicants: H. Lundbeck A/S, Vernalis (R&D) Ltd.Inventors: Gitte Kobberøe Mikkelsen, Laurent David, Stephen Watson, Garrick Paul Smith, Douglas Stewart Williamson, I-Jen Chen
-
Patent number: 9321748Abstract: The present invention is directed to aminopyridine derived compounds of formula (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.Type: GrantFiled: December 30, 2013Date of Patent: April 26, 2016Assignees: H. Lundbeck A/S, Vernalis (R&D) Ltd.Inventors: Gitte Kobberøe Mikkelsen, Laurent David, Stephen Watson, Garrick Paul Smith, Douglas Stewart Williamson, I-Jen Chen